Analysis of molecular breakpoint and m‐RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival

British Journal of Haematology

Volumn 89, Issue 3, 1995, Pages 546-554

  Shepherd, Patricia ^a   Suffolk, Ruth ^a   Halsey, Jim ^b   Allan, Norman ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

CML; cytogenetic response; DNA analysis; prognosis; RNA analysis

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; DNA; RNA;

ARTICLE; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; BASE SEQUENCE; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR; RNA SPLICING; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 0028960453     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1995.tb08362.x     Document Type: Article

References (34)

1. Molecular analysis in chronic granulocytic leukaemia: location of breakpoints within M‐BCR and relationship with presentation platelet counts
2. Philadelphia‐positive chronic mayelogenous leukemia with breakpoint 5′ of the breakpoint cluster region but within the bcr gene
3. Clinical stage of chronic granulocytic leukaemia and bcr breakpoint location in South‐East Asian patients
4. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia
5. Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia
6. A possible correlation between the type of bcr‐abl hybrid messenger RNA and platelet count in Philadelphia‐positive chronic myelogenous leukemia
7. The relationship between the type of bcr‐abl hybrid messenger RNA and thrombopoiesis in Philadelphia‐positive chronic myelogenous leukemia
8. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α‐interferon in chronic myelogenous leukemia
9. The position of the M‐BCR breakpoint does not predict the duration of chronic or survival in chronic myeloid leukaemia
10. Does the breakpoint within the major breakpoint cluster region (M‐bcr) influence the duration of chronic phase in chronic myeloid leukemia? An analytical comparison of current literature
11. Further evidence that the site of the breakpoint in the major breakpoint cluster region (M‐bcr) may be a prognostic indicator
12. The site of the breakpoint within the bcr is a prognostic factor in Philadelphiapositive CML patients
13. Use of pulsed field gel electrophoresis to characterize BCR gene involvement in CML patients lacking M‐BCR rearrangement
14. Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase
15. A new chromosomal breakpoint in Ph positive, bcr negative chronic myelogenous leukemia
16. No correlation between location of bcr breakpoints and clinical states in Ph‐positive CML patients
17. Breakpoint localization within the M‐bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy
18. No correlation between site of breakpoint in the bcr gene and platelet counts in Philadelphia chromosome‐positive CML
19. No correlation between the type of bcr‐abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia
20. New type of bcr/abl junction in Philadelphia chromosome‐positive chronic myeloid leukemia
21. Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human malignancies
22. CML patients in blast crisis have breakpoints localized to a specific region of the BCR
23. Chronic myeloid leukemia may be associated with several bcr‐abl transcripts including the acute lymphoid leukemia‐type 7kb transcript
24. Molecular breakpoints and platelet counts in chronic myeloid leukemia
25. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia‐positive chronic myeloid leukemia
26. Prognostic discrimination in ‘good risk’ chronic granulocytic leukemia
27. Bcr gene rearrangement and expression in chronic myelocytic leukemia
28. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia
29. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease
30. 1‐positive chronic myeloid leukaemia
31. M‐BCR break‐point location does not predict survival in Philadelphia chromosomepositive chronic myeloid leukemia
32. Alternative BCR/ABL transcripts in chronic myeloid leukemia